BMS-1001 NEW
| Price | $56 | $133 | $197 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: BMS-1001 | CAS No.: 2113650-03-4 |
| Purity: 98.89% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | BMS-1001 |
| Description | BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay). |
| In vitro | The small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 , ?bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins.?The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1.?BMS-1001 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.?Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 1.14 mg/mL (1.92 mM), Solution. DMSO : 11.36 mg/mL (19.1 mM), Sonication is recommended. |
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | BMS-1001 | BMS1001 | BMS 1001 |
| Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | BMS-1166-n-piperidine-co-n-piperazine dihydrochloride | IMMH 010 maleate | Icariside I | Fraxinellone | Pembrolizumab | LSD1-IN-27 | Acesulfame Potassium | Anti-Mouse PD-1 Antibody (RMP1-14) | Panaxadiol | JQ-1 (carboxylic acid) |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | PPI Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1700.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $46.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-08-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY